Axcend Health Sp. z o.o. (Poland)

Main Activities: Research and Development in Biotechnology (except Nanobiotechnology)

Secondary Activities: All Other Information Services | Lessors of Real Estate | Office Machinery and Equipment Rental and Leasing | Engineering Services | Computer Systems Design and Related Services | Administrative Management and General Management Consulting Services | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Full name: Axcend Health Sp. z o.o.

Profile Updated: October 22, 2024

Axcend Health Sp. z o.o. is an enterprise based in Poland. Its main office is in Warsaw. The company operates in the Research and Development in Biotechnology (except Nanobiotechnology) sector. It was incorporated on September 19, 2017. Its total assets decreased by 71.7% over the same period.

Headquarters
Ul. Choragwi Pancernej 51
Warsaw; Mazowieckie; Postal Code: 02-951

Contact Details: Purchase the Axcend Health Sp. z o.o. report to view the information.

Basic Information

Registered Capital:

Purchase the Axcend Health Sp. z o.o. report to view the information.

Financial Auditors:

Purchase the Axcend Health Sp. z o.o. report to view the information.

Incorporation Date:

September 19, 2017

Key Executives

Purchase this report to view the information.

President

Ownership Details

Purchase this report to view the information.

60%

Purchase this report to view the information.

32%

Subsidiaries

Healtharc Sp. z o.o.

100%

Isovines Sp. z o.o.

20%

Inthervax Sp. z o.o.

10%

Company Performance

Financial values in the chart are available after Axcend Health Sp. z o.o. report is purchased.

Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service

Key Financial Highlights

Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.

Operating profit (EBIT)

10.73%▲

EBITDA

10.73%▲

Net Profit (Loss) for the Period

30.79%▲

Total Assets

-71.7%▼

Total Equity

-46.82%▼

Return on Equity (ROE)

-20.38%▼

Quick Ratio

1.07%▲

Cash Ratio

0.78%▲

Similar companies